µå·¯±×ÀÎÆ÷¸ÞÀÎ
 

»óº´Äڵ忡 µû¸¥ »óº´¸íÀ» È®ÀÎ ÇϽǼö ÀÖ½À´Ï´Ù.  
»óº´ÄÚµå ÇÑ±Û»óº´¸í ¿µ¹®»óº´¸í
G129 »ó¼¼ºÒ¸íÀÇ Ã´¼ö¼º ±ÙÀ§Ãà Spinal muscular atrophy, unspecified
G13 ´Þ¸® ºÐ·ùµÈ Áúȯ¿¡¼­ÀÇ ÀÏÂ÷ÀûÀ¸·Î ÁßÃ߽Űæ°èÅë¿¡ ¿µÇâÀ» ÁÖ´Â °èÅ뼺 À§Ãà Systemic atrophies primarily affecting central nervous system in diseases classified elsewhere
G130 ½Å»ý¹°µþ¸² ½Å°æ±Ùº´Áõ ¹× ½Å°æº´Áõ Paraneoplastic neuromyopathy and neuropathy
G130 ¾ÏÁ¾¼º ½Å°æ±ÙÀ°º´Áõ Carcinomatous neuromyopathy (C00-C97+)
G130 °¨°¢¼º ½Å»ý¹°µþ¸² ½Å°æº´Áõ[µ¥´Ïºê¶ó¿î] Sensorial paraneoplastic neuropathy [Denny Brown](C00-D48+)
G131 ½Å»ý¹°Áúȯ¿¡¼­ ÀÏÂ÷ÀûÀ¸·Î ÁßÃ߽Űæ°èÅëÀ» ħ¹üÇÏ´Â ±âŸ °èÅ뼺 À§Ãà Other systemic atrophy primarily affecting central nervous system in neoplastic disease
G131 ½Å»ý¹°µþ¸² º¯¿¬ºÎ³úº´Áõ Paraneoplastic limbic encephalopathy (C00-D48+)
G132 Á¡¾×ºÎÁ¾¿¡¼­ ÀÏÂ÷ÀûÀ¸·Î ÁßÃ߽Űæ°èÅëÀ» ħ¹üÇÏ´Â °èÅ뼺 À§Ãà Systemic atrophy primarily affecting central nervous system in myxoedema (E00.1+, E03.-+)
G138 ´Þ¸® ºÐ·ùµÈ ±âŸ Áúȯ¿¡¼­ ÀÏÂ÷ÀûÀ¸·Î ÁßÃ߽Űæ°èÅëÀ» ħ¹üÇÏ´Â °èÅëÀû À§Ãà Systemic atrophy primarily affecting central nervous system in other diseases classified elsewhere
G14 ¼Ò¾Æ¸¶ºñÈÄ ÁõÈıº Postpolio syndrome
G14 ¼Ò¾Æ¸¶ºñÈÄ Ã´¼ö¼º ÁõÈıº Postpolio myelitic syndrome
G20 ÆÄŲ½¼ º´ Parkinson's disease
G20 ¹ÝÆÄŲ½¼Áõ Hemiparkinsonism
G20 ¶³¸²¸¶ºñ Paralysis agitans
G20 ÆÄŲ½¼Áõ ¶Ç´Â ÆÄŲ½¼º´ NOS Parkinsonism or Parkinson's disease NOS
G20 Ư¹ß¼º ÆÄŲ½¼Áõ ¶Ç´Â ÆÄŲ½¼º´ Idiopathic Parkinsonism or Parkinson's disease
G20 ÀÏÂ÷¼º ÆÄŲ½¼Áõ ¶Ç´Â ÆÄŲ½¼º´ Primary Parkinsonism or Parkinson's disease
G21 ÀÌÂ÷¼º ÆÄŲ½¼Áõ Secondary parkinsonism
G210 ¾Ç¼º ½Å°æÀÌ¿ÏÁõÈıº Malignant neuroleptic syndrome
G211 ±âŸ ¾à¹°-À¯¹ß ÀÌÂ÷¼º ÆÄŲ½¼Áõ Other drug-induced secondary parkinsonism
2381  2382  2383  2384  [2385] 2386  2387  2388  2389  2390